H.C. Wainwright analyst Raghuram Selvaraju says recent takeovers in the neurology arena underscores the opportunity in shares of Reviva Pharmaceuticals. (RVPH). The recent buyouts of Karuna Therapeutics (KRTX) and Cerevel Therapeutics (CERE) “serve to emphasize the clear opportunity for investors in Reviva shares, particularly since Reviva trades at a market cap of $130M,” the analyst tells investors in a research note. The firm reminds investors that Reviva has a “risk-mitigated” lead asset, brilaroxazine, in late-stage development for treatment of schizophrenia “that boasts a highly favorable efficacy and safety profile.” Wainwright believes Reviva may be the most undervalued and underrated publicly traded company in the neurology arena today. It reiterates a Buy rating on the shares with a $20 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RVPH:
- Reviva to Participate in the Zacks Small-Cap Research Life Sciences Investor Forum
- Largest borrow rate increases among liquid names
- Reviva Announces Closing of $30 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Reviva to sell 5.85M shares at $5.125 in registered direct offering
- Reviva Reports Third Quarter 2023 Financial Results and Recent Business Highlights